| Title: | Genome-wide association study of medication-use and associated disease in the UK Biobank |
| Journal: | Nat Commun |
| Published: | 23 Apr 2019 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/31015401/ |
| DOI: | https://doi.org/10.1038/s41467-019-09572-5 |
Publication 3453
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Genome-wide association studies (GWASs) of medication use may contribute to understanding of disease etiology, could generate new leads relevant for drug discovery and can be used to quantify future risk of medication taking. Here, we conduct GWASs of self-reported medication use from 23 medication categories in approximately 320,000 individuals from the UK Biobank. A total of 505 independent genetic loci that meet stringent criteria (P < 10-8/23) for statistical significance are identified, mainly a reflection of medication-relevant indications. We investigate the implications of these GWAS findings in relation to biological mechanism, potential drug target identification and genetic risk stratification of disease. Amongst the medication-associated genes are 16 known therapeutic-effect target genes for medications from 9 categories. Two of the medication classes studied are for disorders that have not previously been subject to large GWAS (hypothyroidism and gastro-oesophageal reflux disease).1 Author
- Wu Y et al.
1 Application
| Application ID | Title |
|---|---|
| 12514 | The limits of predicting complex traits and diseases from genetic data |
Enabling scientific discoveries that improve human health